紫杉醇联合草酸铂治疗初治晚期非小细胞肺癌的疗效  

Efficacy of combined paclitaxel and oxaliplatin therapy in patients with chemotherapy-naive advaced non-small cell lung cancer

作　　者：林动[1] 徐海鹏[1] 何志勇[1] 

机构地区：[1]福建省肿瘤医院内科,福州350001

出　　处：《海峡药学》2007年第6期78-80,共3页Strait Pharmaceutical Journal

摘　　要：目的 观察紫杉醇联合草酸铂治疗晚期非小细胞肺癌的疗效及不良反应。方法41例患者均为初治晚期非小细胞肺癌（NSCLC）。化疗方案为：紫杉醇135mg·m^2，静滴≥3h；草酸铂130mg·m^2，静滴≥2h，均在第一天完成，21d为一周期，连用2-6周期。结果41例均顺利完成2周期以上化疗，可评价疗效，有效率为34．1％（14／41），中位无进展生存时间为6．0个月，中位生存时间为10．7个月，1年生存率为39．O％（16／41），毒副反应方面，Ⅲ＋Ⅳ度白细胞下降率为4．9％，无Ⅲ＋Ⅳ度血小板下降者，Ⅲ＋Ⅳ度恶心呕吐率为7．3％，Ⅲ＋Ⅳ度神经损害率为9．8％，无Ⅲ＋Ⅳ度肾功能损害者，无Ⅲ＋Ⅳ度肌肉关节疼痛者。结论紫杉醇联合草酸铂治疗晚期NSCLC有一定疗效，不良反应较少，值得进一步研究。OBJECTIVE Paclitaxel plus cisplatin is an effective regiment in the treatment of non-small cell lung cancer（NSCLC） ,but it has severe adverse toxicities. The aim of this clinical trial is to evaluate the effect and safety of paclitaxel plus oxaliplatin in the treatment of advanced NSCLC. METHODS Forty-one patients with chemotherapy-naive advanced NSCLC were enrolled into this trial. All received paclittaxel（ 135mg/m2 ,intravenous infusion over 3 hours on day 1 ）and oxaliplatin（ 130mg/m^2 ,intravenous infusion over 2 hours on day 1 ） every 21 days. Two to six cycles were given to patients. RESULTS All patients were evaluated and received at least 2 cycles chemotherapy. The response rate was 34. 1% （14/41）, median time to progression was 6. 0 months, median survival time was 10. 7 months, 1-year survival was 39.0% （ 16/41 ）. The severe adverse effects were as follow：the incidence rate of Ⅲ ＋Ⅳ leukopenia was 4.9%, Ⅲ ＋Ⅳnausea and vomiting was 7. 3% Ⅲ ＋ IV nerve abnormality was 9.8%. Noll[ ＋ IV thrombocytopenia, 11I ＋ IVimpaired renal function, Ⅲ ＋ Ⅳmyalgia and anthralgia were encountered. CONCLUSION This regimen of paclitaxel plus oxaliplatin combination is well tolerated, demonstrates activity in patients with advanced NSCLC,and deserves further evaluation.

关 键 词：晚期非小细胞肺癌 紫杉醇 草酸铂 化学治疗 

分 类 号：R979.14[医药卫生—药品]